Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Prolanta |
Synonyms | |
Therapy Description |
Prolanta is a prolactin-based peptide containing a G129R mutation that acts as an antagonist of the prolactin receptor, leading to increased autophagy and cell death, and potentially resulting in decreased tumor growth (PMID: 24703838). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Prolanta | Prolanta is a prolactin-based peptide containing a G129R mutation that acts as an antagonist of the prolactin receptor, leading to increased autophagy and cell death, and potentially resulting in decreased tumor growth (PMID: 24703838). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02534922 | Phase I | Prolanta | Study of Prolanta in Recurrent or Persistent Epithelial Ovarian Cancer (ProlantaOC) | Unknown status | USA | 0 |